PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

MEWBURN ELLIS LLP
City Tower
40 Basinghall Street
London
Greater London EC2V 5DE
ROYAUME UNI

RECEIVED
15 MAY 2020
BRISTOL

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(PCT Rule 71.1)

Date of mailing *(day/month/year)*	12.05.2020
Applicant's or agent's file reference 007441454	**IMPORTANT NOTIFICATION**

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP2019/054685	26.02.2019	27.02.2018

Applicant
ZEALAND PHARMA A/S

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:	Authorized Officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Fax: +49 89 2399 - 4465	Papiol Rovira, M Tel. +49 89 2399-7199

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 007441454	**FOR FURTHER ACTION**	See Form PCT/IPEA/416
International application No. PCT/EP2019/054685	International filing date *(day/month/year)* 26.02.2019	Priority date *(day/month/year)* 27.02.2018
International Patent Classification (IPC) or national classification and IPC INV. C07K7/08		
Applicant ZEALAND PHARMA A/S		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. ☒ *(sent to the applicant and to the International Bureau)* a total of 37 sheets, as follows:
      ☒ sheets of the description, claims and/or drawings which have been amended and/or sheets containing rectifications authorized by this Authority, unless those sheets were superseded or cancelled, and any accompanying letters (see Rules 46.5, 66.8, 70.16, 91.2, and Section 607 of the Administrative Instructions).
      ☐ sheets containing rectifications, where the decision was made by this Authority not to take them into account because they were not authorized by or notified to this Authority at the time when this Authority began to draw up this report, and any accompanying letters (Rules 66.4bis, 70.2(e), 70.16 and 91.2).
      ☐ superseded sheets and any accompanying letters, where this Authority either considers that the superseding sheets contain an amendment that goes beyond the disclosure in the international application as filed, or the superseding sheets were not accompanied by a letter indicating the basis for the amendments in the application as filed, as indicated in item 4 of Box No. I and the Supplemental Box (see Rule 70.16(b)).
   b. ☐ *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing, in the form of an Annex C/ST.25 text file, as indicated in the Supplemental Box Relating to Sequence Listing (see paragraph 3*ter* of Annex C of the Administrative Instructions).

4. This report contains indications relating to the following items:
   - ☒ Box No. I Basis of the report
   - ☐ Box No. II Priority
   - ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - ☐ Box No. IV Lack of unity of invention
   - ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - ☐ Box No. VI Certain documents cited
   - ☐ Box No. VII Certain defects in the international application
   - ☐ Box No. VIII Certain observations on the international application

Date of submission of the demand	Date of completion of this report
23.12.2019	12.05.2020
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Fax: +49 89 2399 - 4465	Authorized officer Pinheiro Vieira, E Telephone No. +49 89 2399-7865

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/EP2019/054685

Box No. I Basis of the report

1. With regard to the **language**, this report is based on

   ☒ the international application in the language in which it was filed

   ☐ a translation of the international application into , which is the language of a translation furnished for the purposes of:
   - ☐ international search (under Rules 12.3(a) and 23.1(b))
   - ☐ publication of the international application (under Rule 12.4(a))
   - ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a) and (b))

2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages

1-83 as originally filed

Claims, Numbers

1-44 filed with the letter of 23-12-2019

Drawings, Sheets

1/3-3/3 as originally filed

☐ a sequence listing - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since either they are considered to go beyond the disclosure as filed, or they were not accompanied by a letter indicating the basis for the amendments in the application as filed, as indicated in the Supplemental Box (Rules 70.2(c) and (c-*bis*)):
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:

5. ☐ This report has been established:
   - ☐ taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rules 66.1(d-*bis*) and 70.2(e)).
   - ☐ without taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91(Rules 66.4*bis* and 70.2(e)).

6. ☒ With regard to top-up searches (Rules 66.1 *ter* and 70.2(f)):
   - ☒ A top-up search was carried out by this Authority on 29.04.2020 (all discovered documents are listed in the Supplemental Box Relating to Top-up Search).
     - ☐ Additional relevant documents have been discovered during the top-up search.
   - ☐ No top-up search was carried out by this Authority because it would serve no useful purpose.

7. ☐ Supplementary international search report(s) from Authority(ies) has/have been received and taken into account in establishing this report (Rule 45bis.8(b) and (c)).

* *If item 4 applies, some or all of those sheets may be marked "superseded".*

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-44
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-44
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-44
	No:	Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Re Item V

1 Cited documents.

1.1 Reference is made to the following documents:

D1 US 2014/113874 A1 (LAMBRIS JOHN D [US] ET AL) 24 April 2014 (2014-04-24)

D2 EP 2 424 557 A1 (UNIV PENNSYLVANIA [US]) 7 March 2012 (2012-03-07)

D3 BELLOWS M L ET AL: "New Compstatin Variants through Two De Novo Protein Design Frameworks", BIOPHYSICAL JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 98, no. 10, 19 May 2010 (2010-05-19), pages 2337-2346, XP002632554, ISSN: 0006-3495, DOI: 10.1016/J.BPJ.2010.01.057 [retrieved on 2010-05-18]

D4 WO 2014/078734 A2 (APELLIS PHARMACEUTICALS INC [US]) 22 May 2014 (2014-05-22)

D5 WO 2014/100407 A1 (UNIV CALIFORNIA [US]; UNIV PRINCETON [US]; UNIV CYPRUS [CY]) 26 June 2014 (2014-06-26)cited in the application

1.2 D1 to D5 discloses compstatin analogues with Val at position 3.

2 Novelty and Inventive step (Article 33 PCT)

2.1 None of the cited documents discloses or suggests a compstatin analogue having Ile3 and Glu9. Novelty is therefore, acknowledged (Art. 33(2) PCT)

2.2 Any document could be considered the closest prior art document. They all disclose compstatin analogues capable of binding to C3 protein and inhibiting complement activation.

2.3 The replacement of Val3 by Ile3 leads to compounds having a better solubility and greater activity. The present problem to be solved can therefore, be seen as the provision of compstatin analogues having improved activity and solubility.

The Applicant solves the problem by providing the claimed compounds where Val3 is replaced by Ile3.

The Applicant has shown by the examples that the posed problem has been credibly solved. An increase in solubility as well as a greater activity was obtained for compounds showing the mutation at position 3 (see tables 1 to 4, 6 and 7). The Applicant has also validated the position 3 by comparing activity changes with several amino acids at position 3 (see table 4).

Bearing in mind that none of the cited documents discloses ou suggests Ile3 at position 3 in addition to Glu at position 9, a position considered conserved and important for binding to protein C3, and that the Applicant has shown that said position could be modified by Ile3 without loss of activity it is considered that the present set of claims on file is inventive. To note is that it is accepted a broader structure for the peptide based on the data provided and bearing in mind that positions 2, 3, 5, 7,9, 10 and 12 are conserved.

The claimed subject matter is therefore, considered to comply with the requirements of Art. 33(3) PCT.

2.4 Although claims 40, 41, 43 and 44 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound. Patentability, in particular novelty and inventive step, of said claims has been assessed on the basis of a purpose-limited product claim taking into account the alleged effects of the compound.

The patentability can be dependent upon the formulation of the claims. The EPO, for example, does not recognise as patentable claims to the use of a compound in medical treatment, but may allow claims to a product, in particular substances or compositions for use in a first or further medical treatment.

Mewburn Ellis

City Tower
40 Basinghall Street
London EC2V 5DE
United Kingdom
T +44 (0)20 7776 5300
F +44 (0)330 111 4455

mewburn.com
mail@mewburn.com

European Patent Office
Acting as International Preliminary Examining Authority
D-80298 München
Germany

23 December 2019

Dear Sirs

International Patent Application No. PCT/EP2019/054685
Applicant: ZEALAND PHARMA A/S
Our Ref: GRF/BP7441454

This letter accompanies the Chapter II Demand filed in connection with this application.

1. Fees

The following fees are being paid online today:

PCT Preliminary Examination Fee	Euro	**1830.00**
PCT Handling Fee	Euro	**176.00**
TOTAL:	Euro	**2,006.00**

If any additional fees are required so that this Chapter II Demand is deemed to be filed, then the EPO is authorised to deduct such fees from my firm's deposit account number 2805.0013 under the reference SHORTFALL, informing me in writing that this has been done.

2. Amendments

Amended claims 1-44 are filed under Article 34 PCT.

For the examiner's convenience a marked-up version is included for reference only.

Claims 1-4, 10 and 12-14 are amended to specify that the residue present at position X9 is glutamic acid (E; Glu). Basis is found in the original versions of those claims. Subsequent claims have been adapted for consistency where necessary.

4. Novelty

None of the prior art documents cited in the International Search Report or provided with the third party observation of 28 October 2019 describe a compstatin analogue having I at position 3 and E at position 9. For example, see the table at page 3 of "document #9" provided with the third party observation.

5. Inventive Step

The prior art provides no incentive for the skilled person to combine I (Ile) at position 3 with E (Glu) at position 9 as now claimed.

The only reference which mentions I at position 3 is WO 99/13899 ("citation 1" from the third party observation). Notably that document contains no exemplification of molecules having I at position 3, so the reader would be unaware whether such a substitution was technically viable.

In the generic formula on pages 15-16, X9 is listed as "*any amino acid, preferably His or Ala*". It appears that only H (His; the original compstatin residue) is exemplified at that position.

The present application contains data showing that the combination of I3 and E9 is particularly advantageous. For example, the table below shows data for compounds having similar backbone sequences, presented in rank order of their complement inhibitory activity (low to high). The compounds having I3 all have greater inhibitory activity (i.e. lower IC50) than those having V3, and those having the combination of I3 and E9 have the highest inhibitory activity of all.

Compound		**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**		**CP hemolysis IC50 (nM)**
E	Ac	I	C(1)	**V**	W	Q	D	W	G	A	H	S	C(1)	T	NH_2	>1000
F	Ac	I	C(1)	**V**	W	Q	D	W	G	E	H	S	C(1)	T	NH_2	540
A	Ac	I	C(1)	**V**	W	Q	D	W	G	E	H	R	C(1)	T	NH_2	350
4W9A	Ac	I	C(1)	**V**	W	Q	D	W	G	A	H	R	C(1)	T	NH_2	250
1	Ac	I	C(1)	**I**	W	Q	D	W	G	A	H	R	C(1)	T	NH_2	150
19	Ac	I	C(1)	**I**	W	Q	D	W	G	A	H	S	C(1)	T	NH_2	140
2	Ac	I	C(1)	**I**	W	Q	D	W	G	**E**	H	R	C(1)	T	NH_2	94
20	Ac	I	C(1)	**I**	W	Q	D	W	G	**E**	H	S	C(1)	T	NH_2	59

Clearly the combination of I3 and E9 is not suggested by WO 99/13899 ("citation 1"). None of the other documents point to the use of E (Glu) at position 9 at all, still less in combination with I3. (Again, see the summary table provided in "document #9" of the third party observation.) Thus it is impossible to arrive at the claimed combination from the cited documents.

We note that citations 1 to 7 provided by the third party apparently originate from the same research group (or at least share a common inventor / author of John D Lambris). Despite WO 99/13899 ("citation 1") being published as long ago as March 1999, none of the subsequent documents appear to have adopted the suggestion to use Ile (or any other residue) at position 3 instead of Val. Rather, Val3 appears to be regarded as essential in all of those disclosures. See claim 1 of each of citations 4-7, for example. The same applies to citation 8, from a different group. This strongly suggests that the claimed invention is not obvious.

Mewburn Ellis

The present application therefore shows for the first time that compstatin analogues having the residues I3 and E9 can be highly active, and even superior to compounds having more commonly used residues at those positions in a similar peptide backbone. This could not have been predicted from the prior art.

We therefore believe that the claims as amended are both novel and inventive.

6. Closing Remarks

It is requested that an International Preliminary Report on Patentability (IPRP/Chapter II) be issued indicating that all claims are novel, inventive, and industrially applicable.

In the event the Examiner considers that any objections remain outstanding, we ask that a further written opinion be issued as soon as possible, in view of the limited period allowed for the IPE procedure.

Yours faithfully

/GRAHAM R FORREST/

Graham R Forrest
Appointed Agent
For and on behalf of Mewburn Ellis LLP (Association No. 929)
graham.forrest@mewburn.com

To contact me personally
please telephone + 44 117 945 1234

Claims:

1. A compstatin analogue represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-X8-E-H-X11-C-X13-R2-Y2 (Formula I)

wherein:

Y1 is hydrogen, acetyl or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, F, V, Y, 1-Me-Trp, D-Trp, N-Me-Trp, 1-For-Trp, 1-Nal, 2-Nal, 5-Me-Trp, Bpa or 2-Igl;

X6 is E, K or D;

X8 is G or Sar;

X11 is R, S or K;

X13 is T, S, E, F, H, K, Sar, G, I, D, N-Me-Ile or N-Me-Thr;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue optionally has a lipophilic group Φ covalently linked to the side chain of one or more amino acid residues;

or a pharmaceutically acceptable salt and/or solvate thereof.

2. A compstatin analogue represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-X8-E-H-X11-C-X13-R2-Y2 (Formula II)

wherein:

Y1 is hydrogen, acetyl, or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp;

X6 is E or D;

X8 is G or Sar;

X11 is R, S or K;

X13 is T, S, E, I, Sar, K, G or N-Me-Ile;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof, or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue optionally has a lipophilic group Φ covalently linked to the side chain of one or more amino acids;

or a pharmaceutically acceptable salt and/or solvate thereof.

3. A compstatin analogue represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-G-E-H-X11-C-X13-R2-Y2 (Formula III)

wherein:

Y1 is hydrogen, acetyl or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, Y,1-Nal, 2-Nal or 1-Me-Trp;

X6 is E or D;

X11 is R, S or K;

X13 is T, I, S, E, K or Sar;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof, or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue optionally has a lipophilic group Φ covalently linked to the side chain of one or more amino acids;

or a pharmaceutically acceptable salt and/or solvate thereof.

4. A compstatin analogue represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-G-E-H-R-C-X13-R2-Y2 (Formula IV)

wherein:

Y1 is hydrogen, acetyl or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp;

X6 is E or D;

X13 is T, S, E or Sar;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof, or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue optionally has a lipophilic group Φ covalently linked to the side chain of one or more amino acids;

or a pharmaceutically acceptable salt and/or solvate thereof.

5. A compstatin analogue according to any one of claims 1 to 4 comprising at least one lipophilic group Φ.

6. A compstatin analogue according to claim 5 wherein Y1 or Y2 is a lipophilic group Φ.

7. A compstatin analogue according to claim 5 or claim 6 comprising a lipophilic group Φ linked to the side chain of an amino acid residue at position X1, X11 or X13, or an amino acid residue in R1 or R2.

8. A compstatin analogue according to claim 7 wherein said amino acid residue is a lysine residue.

9. A compstatin analogue according to any one of claims 1 to 4 which does not comprise a lipophilic group Φ.

10. A compstatin analogue according to claim 1, represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-G-E-H-R-C-X13-R2-Y2 (Formula V)

wherein:

Y1 is hydrogen or acetyl;

X1 is Y or F ;

X4 is W, Y, 1-Me-Trp;

X6 is E or D;

X13 is T, E or Sar;

Y2 is NH_2 or OH;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof, or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

or a pharmaceutically acceptable salt and/or solvate thereof.

11. A compstatin analogue according to claim 10, represented by the formula:

Y1-R1-X1-C-I-[1-Me-Trp]-Q-X6-W-G-E-H-R-C-X13-R2-Y2 (Formula VI)

wherein:

Y1 is hydrogen or acetyl;

X1 is Y or F;

X6 is E or D;

X13 is T, E or Sar;

Y2 is NH_2 or OH;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof, or Peg3, Peg4, or 8-aminooctanoyl, or derivatives thereof; and

R2 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

or a pharmaceutically acceptable salt and/or solvate thereof.

12. A compstatin analogue according to claim 1, represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-X8-E-H-X11-C-X13-R2-Y2 (Formula VIII)

wherein:

Y1 is hydrogen, acetyl or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp;

X6 is E or D;

X8 is G or Sar;

X11 is R, S or K*;

X13 is T, S, E, I, Sar, K, G or N-Me-Ile;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V or Sar, or a corresponding D form thereof;

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg 3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein * indicates that the amino acid residue bears a lipophilic group Φ covalently linked to its side chain;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue comprises at least one lipophilic group Φ;

or a pharmaceutically acceptable salt and/or solvate thereof.

13. A compstatin analogue according to claim 11, represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-G-E-H-X11-C-X13-R2-Y2 (Formula IX)

wherein:

Y1 is hydrogen, acetyl, or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp;

X6 is E or D;

X11 is R, S or K*;

X13 is T,I, S, E, K or Sar;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V or Sar, or a corresponding D form thereof; and

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K* F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg 3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein * indicates that the amino acid residue bears a lipophilic group Φ covalently attached to its side chain;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue comprises at least one lipophilic group Φ;

or a pharmaceutically acceptable salt and/or solvate thereof.

14. A compstatin analogue according to claim 12 or claim 13, represented by the formula:

Y1-R1-X1-C-I-X4-Q-X6-W-G-E-H-R-C-X13-R2-Y2 (Formula X)

wherein:

Y1 is hydrogen, acetyl or a lipophilic group Φ;

X1 is I, Y, F or Sar;

X4 is W, V, 1-Nal, 2-Nal or 1-Me-Trp;

X6 is E or D;

X13 is T, S, E or Sar;

Y2 is NH_2, OH or a lipophilic group Φ;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V or Sar, or a corresponding D form thereof;

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein * indicates that the amino acid residue bears a lipophilic group Φ covalently attached to its amino acid side chain;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue comprises at least one lipophilic group Φ, e.g. exactly one lipophilic group Φ;

or a pharmaceutically acceptable salt and/or solvate thereof.

15. A compstatin analogue according to claim 14, represented by the formula:

Y1-R1-X1-C-I-[1-Me-Trp]-Q-X6-W-G-E-H-R-C-X13-R2-Y2 (Formula XI)

wherein:

Y1 is hydrogen or acetyl;

X1 is Y or F;

X6 is E or D;

X13 is T, E or Sar;

Y2 is NH_2 or OH;

R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K*, F, P, S, T, W, Y, R, V or Sar, or a corresponding D form thereof;

R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K* F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, or βAla, or a corresponding D form thereof; or Peg3 or Peg4, or 8-aminooctanoyl, or derivatives thereof;

wherein * indicates that the amino acid residue bears a lipophilic group Φ covalently attached to its side chain;

wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;

and wherein the compstatin analogue comprises at least one lipophilic group Φ, e.g. exactly one lipophilic group Φ;

or a pharmaceutically acceptable salt and/or solvate thereof.

16. A compstatin analogue according to any one of the preceding claims wherein the 13-mer peptide portion (X1-X13) of the compstatin analogue has a sequence selected from:

[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)[Sar];

[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)T;

[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRC(1)T;

[Sar]C(1)I[1-Me-Trp]QEWGEHRC(1)[Sar];

[Sar]C(1)IWQDWGEHRC(1)T;

FC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar];

FC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)T;

FC(1)I[1-Me-Trp]QDWGEHKC(1)[Sar];

FC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar];

FC(1)I[1-Me-Trp]QDWGEHRC(1)E;

FC(1)I[1-Me-Trp]QDWGEHRC(1)S;

FC(1)I[1-Me-Trp]QDWGEHRC(1)T;

FC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar];

FC(1)I[1-Nal]QDWGEHRC(1)T;

FC(1)I[2-Nal]QDWGEHRC(1)T;

FC(1)IWQDWGEHRC(1)[Sar];

FC(1)IWQDWGEHRC(1)T;

IC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar];

IC(1)I[1-Me-Trp]QDWGEHRC(1)T;

IC(1)I[2-Nal]QDWGEHRC(1)[Sar];

IC(1)IWQDWGEHRC(1)[Sar];

IC(1)IWQDWGEHRC(1)E;

IC(1)IWQDWGEHRC(1)S;

IC(1)IWQDWGEHRC(1)T;

IC(1)IWQDWGEHSC(1)T;

IC(1)IWQEWGEHRC(1)T;

IC(1)IWQKWGEHRC(1)T;

YC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar];

YC(1)I[1-Me-Trp]QDWGEHRC(1)T;

YC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar];

YC(1)I[2Nal]QDWGEHRC(1)T;

YC(1)IWQDWGEHRC(1)T;

YC(1)I[1-Me-Trp]QDWGEH[K*]C(1)[Sar]; and
YC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar].

17. A compstatin analogue according to any one of the preceding claims wherein R1 has a sequence selected from:

{d}Y, EGSE, AGSE, SASE, EYSE, GSE, ASE, ESSA, KGSA, AKGE, ASGE, ASSE, ASES, GSAE, ESSE, ESGA, SEG, GES, ESS, EGSA, ESE, EGE, ESA, SAE, SGA, YLEA, GSA, KEK, EKG, ES, AE, TE, KE, GE, FE, YE, AS, SE, RS, SR, SA, GE, Y, S and E.

18. A compstatin analogue according to claim 17 comprising a lipophilic group Φ covalently linked to an amino acid side chain of R1.

19. A compstatin analogue according to claim 18 wherein R1 has the sequence K*GSA.

20. A compstatin analogue according to any one of the preceding claims wherein R2 has a sequence selected from:

EGASGSG, EGAGSG, EGASAG, EGAGAG, EGESGSG, EGEGSG, EGESAG, EGEGAG, EK[γGlu]AK, EK[γGlu]A , EGEGG, EGAGG, EGESS, GAESK, EGAK, EGEK, EGG, EGK, EGKK, EGS, EK, EGA, EGAK, EK[□Glu], EK[γGlu]-K, EGE[Peg3], EGE[Peg3]-K, EGE[Peg3][Peg3], EGE[Peg3][Peg3]-K, EGE[Peg3][Peg3][Peg3],

EGE[Peg3][Peg3][Peg3]-K GESESE, GAESES, EGESES, EGESESK, EGE[Peg3]-ES, EGE[Peg3]-ESK, GESESE, EGE-[8-aminooctanoyl], EGE-[8-aminooctanoyl]-K, EGE-[8-aminooctanoyl]-EK, EGEGGG, EGEGGGK, EK[γGlu]GGG, EK[γGlu]GGGK, EGE-[8-aminooctanoyl]-E, E[Peg3][Peg3], E[Peg3][Peg3]-K, EA[Peg3][Peg3], EA[Peg3][Peg3]-K, GAES, EYGS, EGYA, EAGS, EAKS, EKSA, ESGA, EGGS, EGGA, ESSG, ESAG, GEES, AEES, ESEG, AEGS, ESGS, SEGA, SEG, EGK, , ESG, EAG, GAE, EGEA, EGE, EA, E, S, GE, GEK, EG, EA, EKE or EKP.

21. A compstatin analogue according to claim 20 comprising a lipophilic group Φ covalently linked to an amino acid side chain of R2.

22. A compstatin analogue according to claim 21 wherein R2 has the sequence EK[γGlu]AK*, EGKK*, EK[γGlu]K*, EGE[Peg3]-K*, EGESESK*, EGE[Peg3]-ESK*, EGE-[8-aminooctanoyl]-K*, EGE-[8-aminooctanoyl]-EK*, EGEGGGK*, EK[γGlu]GGGK*, EGE[Peg3][Peg3]-K*, EGE[Peg3][Peg3][Peg3]-K*, E[Peg3][Peg3]-K*, EA[Peg3][Peg3]-K*, GAESK*, EGAK*, EGEK*, EGK* EGE[Peg3]-ESK*, GESESEK*, GEK* or EK*.

23. A compstatin analogue according to claim 1, comprising a sequence selected from:

IC(1)IWQDWGEHRC(1)T

ESSAIC(1)IWQDWGEHRC(1)T

IC(1)I[1MeTrp]QDWGEHRC(1)T

IC(1)IWQKWGEHRC(1)T

YC(1)IWQDWGEHRC(1)T

ESSAYC(1)IWQDWGEHRC(1)T

[Sar]C(1)IWQDWGEHRC(1)T

IC(1)IWQDWGEHRC(1)[Sar]

ESSAIC(1)IWQDWGEHRC(1)TGAES

IC(1)IWQDWGEHRC(1)TGAES

IC(1)IWQEWGEHRC(1)T

IC(1)IWQDWGEHSC(1)T

IC(1)IWQDWGEHRC(1)S

IC(1)IWQDWGEHRC(1)E

FC(1)IWQDWGEHRC(1)T

IC(1)IWQDWGEHRC(1)TEGE

IC(1)IWQDWGEHRC(1)TEA

IC(1)IWQDWGEHRC(1)TE

IC(1)IWQDWGEHRC(1)EGE

EGSAIC(1)IWQDWGEHRC(1)[Sar]E

EGSAIC(1)IWQDWGEHRC(1)T

EGEIC(1)IWQDWGEHRC(1)T

ESEIC(1)IWQDWGEHRC(1)T

SEIC(1)IWQDWGEHRC(1)TEA

EIC(1)IWQDWGEHRC(1)TE

EIC(1)IWQDWGEHRC(1)TEGE

EGEIC(1)IWQDWGEHRC(1)EGE

ESEIC(1)IWQDWGEHRC(1)EGE

KEKIC(1)IWQDWGEHRC(1)TEKE

EKGIC(1)IWQDWGEHRC(1)TEKP

IC(1)IWQDWGEHRC(1)TEGK

GSAIC(1)IWQDWGEHRC(1)[Sar]E

SAIC(1)IWQDWGEHRC(1)[Sar]E

SAIC(1)IWQDWGEHRC(1)TEG

FC(1)IWQDWGEHRC(1)TGAE

EGSAIC(1)IWQDWGEHRC(1)[Sar]EGE

EGSAFC(1)IWQDWGEHRC(1)[Sar]E

EGSAIC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E

EGSAIC(1)I[2-Nal]QDWGEHRC(1)[Sar]E

IC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES

IC(1)I[2-Nal]QDWGEHRC(1)TGAES

EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E

EGSAIC(1)IWQDWGEHRC(1)TE

EGSAFC(1)I[1-Nal]QDWGEHRC(1)TE

EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)TE

EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)TE

EGSAFC(1)I[2-Nal]QDWGEHRC(1)TE

FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES

YC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES

FC(1)I[1-Nal]QDWGEHRC(1)TGAES

FC(1)I[2-Nal]QDWGEHRC(1)TGAES

YC(1)I[2-Nal]QDWGEHRC(1)TGAES

YC(1)IWQDWGEHRC(1)TGAES

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES

YC(1)I[1-Me-Trp]QDWGEHRC(1)TEAGS

YC(1)I[1-Me-Trp]QDWGEHRC(1)TESGA

EGSAYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]E

SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA

FC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TGAES

{d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TGAES

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]GAES

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA

SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]EA

SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TEA

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E

SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E

EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA

SE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA

SE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA

SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EA

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)SEA

EFC(1)I[1-Me-Trp]QDWGEHRC(1)ES

SEFC(1)I[1-Me-Trp]QDWGEHKC(1)[Sar]EA

GEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA

GE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA

SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRC(1)TEA

SE[Sar]C(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EA

{d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA

24. A compstatin analogue according to claim 1 which is:

Ac-IC(1)IWQDWGEHRC(1)T-NH2 (Compound 2)

Ac-ESSAIC(1)IWQDWGEHRC(1)T-NH2 (Compound 3)

Ac-IC(1)I[1-Me-Trp]QDWGEHRC(1)T-NH2 (Compound 4)

Ac-IC(1)IWQKWGEHRC(1)T-NH2 (Compound 7)

Ac-YC(1)IWQDWGEHRC(1)T-NH2 (Compound 9)

Ac-ESSAYC(1)IWQDWGEHRC(1)T-NH2 (Compound 10)

Ac-[Sar]C(1)IWQDWGEHRC(1)T-NH2 (Compound 11)

Ac-IC(1)IWQDWGEHRC(1)[Sar]-NH2 (Compound 13)

Ac-ESSAIC(1)IWQDWGEHRC(1)TGAES-NH2 (Compound 14)

Ac-IC(1)IWQDWGEHRC(1)TGAES-NH2 (Compound 15)

Ac-IC(1)IWQEWGEHRC(1)T-NH2 (Compound 16)

Ac-IC(1)IWQDWGEHSC(1)T-NH2 (Compound 20)

Ac-IC(1)IWQDWGEHRC(1)S-NH2 (Compound 21)

Ac-IC(1)IWQDWGEHRC(1)E-NH2 (Compound 22)

Ac-FC(1)IWQDWGEHRC(1)T-NH2 (Compound 23)

Ac-IC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 24)

Ac-IC(1)IWQDWGEHRC(1)TEA-NH2 (Compound 25)

Ac-IC(1)IWQDWGEHRC(1)TE-NH2 (Compound 26)

Ac-IC(1)IWQDWGEHRC(1)EGE-NH2 (Compound 27)

Ac-EGSAIC(1)IWQDWGEHRC(1)[Sar]E-NH2 (Compound 28)

Ac-EGSAIC(1)IWQDWGEHRC(1)T-NH2 (Compound 29)

Ac-EGEIC(1)IWQDWGEHRC(1)T-NH2 (Compound 30)

Ac-ESEIC(1)IWQDWGEHRC(1)T-NH2 (Compound 31)

Ac-SEIC(1)IWQDWGEHRC(1)TEA-NH2 (Compound 32)

Ac-EIC(1)IWQDWGEHRC(1)TE-NH2 (Compound 33)

Ac-EIC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 34)

Ac-EGEIC(1)IWQDWGEHRC(1)EGE-NH2 (Compound 35)

Ac-ESEIC(1)IWQDWGEHRC(1)EGE-NH2 (Compound 36)

Ac-KEKIC(1)IWQDWGEHRC(1)TEKE-NH2 (Compound 37)

Ac-EKGIC(1)IWQDWGEHRC(1)TEKP-NH2 (Compound 38)

Ac-IC(1)IWQDWGEHRC(1)TEGK-NH2 (Compound 39)

Ac-GSAIC(1)IWQDWGEHRC(1)[Sar]E-NH2 (Compound 40)

Ac-SAIC(1)IWQDWGEHRC(1)[Sar]E-NH2 (Compound 41)

Ac-SAIC(1)IWQDWGEHRC(1)TEG-NH2 (Compound 42)

Ac-FC(1)IWQDWGEHRC(1)TGAE-NH2 (Compound 43)

Ac-EGSAIC(1)IWQDWGEHRC(1)[Sar]EGE-NH2 (Compound 44)

Ac-EGSAFC(1)IWQDWGEHRC(1)[Sar]E-NH2 (Compound 45)

Ac-EGSAIC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 49)

Ac-EGSAIC(1)I[2-Nal]QDWGEHRC(1)[Sar]E-NH2 (Compound 50)

Ac-IC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-NH2 (Compound 51)

Ac-IC(1)I[2-Nal]QDWGEHRC(1)TGAES-NH2 (Compound 52)

Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 53)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 54)

Ac-EGSAIC(1)IWQDWGEHRC(1)TE-NH2 (Compound 55)

Ac-EGSAFC(1)I[1-Nal]QDWGEHRC(1)TE-NH2 (Compound 56)

Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)TE-NH2 (Compound 57)

Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-NH2 (Compound 58)

Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)TE-NH2 (Compound 59)

Ac-EGSAFC(1)I[2-Nal]QDWGEHRC(1)TE-NH2 (Compound 60)

Ac-FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-NH2 (Compound 61)

Ac-YC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-NH2 (Compound 62)

Ac-FC(1)I[1-Nal]QDWGEHRC(1)TGAES-NH2 (Compound 63)

Ac-FC(1)I[2-Nal]QDWGEHRC(1)TGAES-NH2 (Compound 64)

Ac-YC(1)I[2-Nal]QDWGEHRC(1)TGAES-NH2 (Compound 65)

Ac-YC(1)IWQDWGEHRC(1)TGAES-NH2 (Compound 66)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-NH2 (Compound 67)

Ac-YC(1)I[1-Me-Trp]QDWGEHRC(1)TEAGS-NH2 (Compound 68)

Ac-YC(1)I[1-Me-Trp]QDWGEHRC(1)TESGA-NH2 (Compound 69)

Ac-EGSAYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]E-NH2 (Compound 70)

Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA-NH2 (Compound 71)

Ac-FC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TGAES-NH2 (Compound 72)

H-{d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TGAES-NH2 (Compound 73)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]GAES-NH2 (Compound 74)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA-NH2 (Compound 75)

Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]EA-NH2 (Compound 76)

Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)TEA-NH2 (Compound 77)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 78)

Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E-NH2 (Compound 79)

Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA-NH2 (Compound 80)

Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA-NH2 (Compound 81)

Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA-NH2 (Compound 82)

Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EA-NH2 (Compound 83)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)SEA-NH2 (Compound 84)

Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)ES-NH2 (Compound 85)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHKC(1)[Sar]EA-NH2 (Compound 86)

Ac-GEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA-NH2 (Compound 87)

Ac-GE[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA-NH2 (Compound 88)

Ac-SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRC(1)TEA-NH2 (Compound 89)

Ac-SE[Sar]C(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EA-NH2 (Compound 90)

H-{d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRC(1)TEA-NH2 (Compound 91)

25. A compstatin analogue according to claim 1 comprising a sequence selected from:

[K*]GSAIC(1)IWQDWGEHRC(1)TEGE (Compound 100)

ASGEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*] (Compound 113)

EFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-[K*] (Compound 134)

EGSAIC(1)IWQDWGEHRC(1)TEG-[K*] (Compound 101)

EGSAYC(1)I[1-Me-Trp]QDWGEH[K*]C(1)[Sar]E (Compound 103)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EG-[K*] (Compound 104)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*] (Compound 109)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-[K*] (Compound 110)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]-[K*] (Compound 111)

FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES[K*] (Compound 102)

IC(1)IWQDWGEHRC(1)TEG-[K*] (Compound 92)

IC(1)IWQDWGEHRC(1)TEGE-[K*] (Compound 94)

SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-[K*] (Compound 105)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*] (Compound 119)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*] (Compound 123)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGEGGG-[K*] (Compound 129)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]-[K*] (Compound 138)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]ES-[K*] (Compound 140)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*] (Compound 127)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-[K*] (Compound 139)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]GGG-[K*] (Compound 132)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE-[8-aminooctanoyl]-[K*] (Compound 136)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE-[8-aminooctanoyl]-E-[K*] (Compound 137)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-[K*] (Compound 130)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3]ES-[K*] (Compound 142)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3][Peg3]-[K*] (Compound 126)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEK[γGlu]GGG-[K*] (Compound 133)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*] (Compound 135)

SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*] (Compound 120)
SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3][K*] (Compound 124)
SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*] (Compound 112)
SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*] (Compound 117)
SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*] (Compound 114)
SEYC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar]EK[γGlu]A[K*] (Compound 121)
SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA[K*] (Compound 122)
SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*] (Compound 125)
EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E (Compound 107)
ESSAIC(1)IWQDWGEHRC(1)TEGE (Compound 99)
SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K*] (Compound 143)
SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E[Peg3][Peg3]-[K*] (Compound 144)
EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA[Peg3][Peg3]-[K*] (Compound 145)

26. A compstatin analogue according to claim 25 comprising a sequence selected from:

Ac-[K*]GSAIC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 100)
Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-[NH2] (Compound 113)
Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-[K*]-[NH2] (Compound 134)
Ac-EGSAIC(1)IWQDWGEHRC(1)TEG-[K*]-[NH2] (Compound 101)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH[K*]C(1)[Sar]E-[NH_2] (Compound 103)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EG-[K*]-NH2 (Compound 104)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-NH2 (Compound 109)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-[K*]-NH2 (Compound 110)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]-[K*]-NH2 (Compound 111)
Ac-FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*]-NH2 (Compound 102)
Ac-IC(1)IWQDWGEHRC(1)TEG-[K*]-NH2 (Compound 92,93, 95. 96, 98)
Ac-IC(1)IWQDWGEHRC(1)TEGE-[K*]-NH2 (Compound 94, 97)
Ac-SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-[K*]-NH2 (Compound 105, 106)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*]-NH2 (Compound 119)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2 (Compound 123)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGEGGG-[K*]-NH2 (Compound 129)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]-[K*]-NH2 (Compound 138)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]ES-[K*]-NH2 (Compound 140)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2 (Compound 127, 128)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-[K*]-NH2 (Compound 139, 141)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]GGG-[K*]-NH2 (Compound 132)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]-[K*]-NH2 (Compound 136)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]E-[K*]-NH2 (Compound 137)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-[K*]-NH2 (Compound 130, 131)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3]ES-[K*]-NH2 (Compound 142)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3][Peg3]-[K*]-NH2 (Compound 126)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEK[γGlu]GGG-[K*]-NH2 (Compound 133)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*]-NH2 (Compound 135)
Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*]-NH2 (Compound 120)
Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2 (Compound 124)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*]-NH2 (Compound 112, 118)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2 (Compound 117)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*]-NH2 (Compound 114, 115, 116)
Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar]EK[γGlu]A-[K*]-NH2 (Compound 121)
Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*]-NH2 (Compound 122)
Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*]-NH2 (Compound 125)
Φ-EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 107, 108)
Φ-ESSAIC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 99)
Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K*]-NH2 (Compound 143)
Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E[Peg3][Peg3]-[K*]-NH2 (Compound 144)
Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA[Peg3][Peg3]-[K*]-NH2 (Compound 145)

27. A compstatin analogue according to any one of claims 1 to 8, 12 to 23, 25 or 26 which comprises a lipophilic group Φ, and wherein the lipophilic group Φ is Z^1- or Z^1-Z^2-;

wherein

Z^1 is A–$C_{12\text{-}22}$alkylene–(CO)–;
where A is H or –COOH, and wherein the akylene may be linear or branched and may be saturated or unsaturated, and may optionally incorporate a phenylene or piperazinylene moiety in its length; and

Z^2 is a sequence of 1 to 6 residues of compounds selected from γ-Glu, E, K, Orn, S, T, A, β-Ala, G, P, V, L, I, Y, Q, N, Dapa, Gaba, or Aib, or a correspdoning D form thereof, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, and 10-aminodecanoyl. 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) and (piperazine-1-yl)-carboxylic acid.

28. A compstatin analogue according to claim 27 wherein Z^1 is selected from:
Dodecanoyl i.e. H–$(CH_2)_{11}$–(CO)–;

Tetradecanoyl i.e. H–$(CH_2)_{13}$–(CO)–;

Hexadecanoyl, i.e. H-$(CH_2)_{15}$-(CO)-;

13-carboxytridecanoyl, i.e. HOOC–$(CH_2)_{12}$–(CO)–;

15-carboxypentadecanoyl, i.e. HOOC–$(CH_2)_{14}$–(CO)–;

17-carboxyheptadecanoyl, i.e. HOOC–$(CH_2)_{16}$–(CO)–;

19-carboxynonadecanoyl, i.e. HOOC–$(CH_2)_{18}$–(CO)–; or

21-carboxyheneicosanoyl, i.e. HOOC–$(CH_2)_{20}$–(CO)–

29. A compstatin analogue according to claim 27 or claim 28 wherein Z^2 is selected from:
[γGlu],
[γGlu][Peg3][Peg3]-;
[(Piperazine-1-yl)-acetyl][Peg3][Peg3];
[γGlu]G[γGlu];
[γGlu]K[γGlu];
[γGlu]KG[γGlu]; or
[γGlu]G[Peg3][γGlu][Peg3].
For example, Z^2 may be, or may comprise:

30. A compstatin analogue according to any one of claims 27 to 29 wherein Z^1- or Z1-Z^2- is selected from:
15-carboxy-pentadecanoyl;
15-carboxy-pentadecanoyl[γGlu]-,
15-carboxy-pentadecanoyl[γGlu][Peg3][Peg3]-;
19-carboxy-nonadecanoyl[γGlu][Peg3][Peg3]-;
15-carboxy-pentadecanoyl-[(Piperazine-1-yl)-acetyl][Peg3][Peg3]);
17-carboxy-heptadecanoyl[γGlu]G[γGlu];
17-carboxy-heptadecanoyl[γGlu]K[γGlu];
17-carboxy-heptadecanoyl[γGlu]KG[γGlu];
17-carboxy-heptadecanoyl[γGlu]G(Peg3)[γGlu]-(Peg3);
15-carboxy-hexadecanoyl[γGlu]G[γGlu];
17-carboxy-heptadecanoyl;
17-carboxy-heptadecanoyl[γGlu]]
19-carboxy-nonadecanoyl[γGlu]G[γGlu];and
17-carboxy-heptadecanoyl[γGlu][Peg3][Peg3].

31. A compstatin analogue according to claim 1 which is:

Ac-IC(1)IWQDWGEHRC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (Compound 92)
Ac-IC(1)IWQDWGEHRC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 93)
Ac-IC(1)IWQDWGEHRC(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 94)
Ac-IC(1)IWQDWGEHRC(1)TEG-K((15-carboxy-pentadecanoyl)-[(Piperazine-1-yl)-acetyl][Peg3][Peg3])-NH2 (Compound 95)
Ac-IC(1)IWQDWGEHRC(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 96)
Ac-IC(1)IWQDWGEHRC(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 97)
Ac-IC(1)IWQDWGEHRC(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 98)
[15-Carboxy-pentadecanoyl]-ESSAIC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 99)

Ac-[K([15-carboxy-pentadecanoyl]-
[γGlu][Peg3][Peg3])]GSAIC(1)IWQDWGEHRC(1)TEGE-NH2 (Compound 100)
Ac-EGSAIC(1)IWQDWGEHRC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (Compound 101)
Ac-FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 102)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-C(1)[Sar]E-NH2 (Compound 103)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Compound 104)
Ac-SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (Compound 105)
Ac-SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 106)
[15-Carboxy-pentadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 107)
[17-Carboxy-heptadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-NH2 (Compound 108)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 109)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 110)
Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])]-NH2 (Compound 111)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])]-NH2 (Compound 112)
Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu)-G[γGlu])-NH2 (Compound 113)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Compound 114)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Compound 115)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2 (Compound 116)
Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 117)

Ac-SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[Peg3][γGlu][Peg3])-NH2 (Compound 118)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[Peg3][γGlu][Peg3])-NH2 (Compound 119)

Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[Peg3][γGlu][Peg3])-NH2 (Compound 120)

Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu]-[Peg3])-NH2 (Compound 121)

Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G-[Peg3][γGlu][Peg3])-NH2 (Compound 122)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 123)

Ac-SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 124)

Ac-SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 125)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 126)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K[(15-carboxy-pentadecanoyl)[γGlu]G[γGlu]])-NH2 (Compound 127)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K[(19-carboxy-nonadecanoyl)[γGlu]G[γGlu])-NH2 (Compound 128)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 129)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 130)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-K([15-carboxy-pentadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 131)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 132)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 133)

Ac-EFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 134)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (Compound 135)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 136)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 137)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Compound 138)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 139)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 140)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (Compound 141)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (Compound 142)

Ac-SEFC(1)I[1-Me-Trp]QDWGEHR[C(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 143)

Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 144)

Ac-EF[C(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 145)

32. A composition comprising a compstatin analogue according to any one of claims 1 to 31, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a carrier.

33. A composition according to claim 32, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising a compstatin analogue according to any one of claims 1 to 31, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable carrier, excipient or vehicle.

35. A compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 for use in therapy.

36. A compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 for use in a method of inhibiting complement activation.

37. The compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, for use according to claim 36, wherein inhibiting complement activation comprises one or more biological activities selected from (1) binding to C3 protein, (2) binding to C3b protein and/or (3) inhibiting the cleavage of native C3 by C3 convertases.

38. A compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 for use in a method of prophylaxis or treatment ofage-related macular degeneration, Stargardt disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer, and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiecstasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemias, psoriasis, hidradentitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomeropathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn´s disease, ulcerative colitis or antiphospholipid syndrome.

39. A compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 for use in a method of inhibiting complement activation that occurs during cell or organ transplantation.

40. A method of inhibiting complement activation for treating a subject in need thereof, the method comprising administering to the subject a compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 thereby to inhibit complement activation in the subject.

41. The method of claim 40, wherein the subject hasage-related macular degeneration, Stargardt disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer, and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiecstasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemias, psoriasis, hidradentitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomeropathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn´s disease, ulcerative colitis or antiphospholipid syndrome, the method comprising administering to the subject a compstatin analogue according to any one of claims 1 to 30.

42. An *ex vivo* method of inhibiting complement activation during extracorporeal shunting of a physiological fluid, the method comprising contacting the physiological fluid with a compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31, thereby inhibiting complement activation.

43. Use of a compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31, in the preparation of a medicament for inhibiting complement activation.

44. Use of a compstatin analogue, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 31 in the preparation of a medicament for the treatment ofage-related macular degeneration, Stargardt disease, periodontitis,

diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer, and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiecstasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemias, psoriasis, hidradentitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomeropathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn´s disease, ulcerative colitis or antiphospholipid syndrome.

BNSDOCID: <XS_____2006100103CF_I_>